Review of Industrial Organization

, Volume 55, Issue 1, pp 111–135 | Cite as

The Single Market in Pharmaceuticals

  • Margaret K. KyleEmail author


This paper examines the state of the single market in the European Union (EU) for pharmaceuticals. As with other products, the EU has adopted a number of institutions and policies to encourage integration and the free movement of goods. Over time, member states are more similar in the availability of pharmaceutical products, as well as in the patents that protect them. New pharmaceuticals are generally available sooner and in more EU members. However, there are large differences in the number and mix of products across member states. Because the pricing of pharmaceuticals remains a national competence, price variation also persists—though this may be desirable from a social welfare standpoint.


European Union Integration Intellectual property Parallel trade Pharmaceuticals Regulation 



I thank the editors, Carmine Ornaghi, and two anonymous referees for useful comments and suggestions, as well as participants at the conference “Celebrating 25 Years of the EU Single Market” in April 2018. Access to the IMS MIDAS data that were used was provided through a third-party agreement with Pfizer. The views expressed are my own, and I am responsible for all errors.


  1. Budish, E., Roin, B. N., & Williams, H. (2015). Do firms underinvest in long-term research? Evidence from cancer clinical trials. American Economic Review, 105(7), 2044–2085.CrossRefGoogle Scholar
  2. Cockburn, I., Lanjouw, J., & Schankerman, M. (2016). Patents and the global diffusion of new drugs. American Economic Review, 106(1), 136–164.CrossRefGoogle Scholar
  3. Cremers, K., Gaessler, F., Harhoff, D., Helmers, C., & Lefouili, Y. (2016). Invalid but infringed? An analysis of the bifurcated patent litigation system. Journal of Economic Behavior & Organization, 131, 218–242.CrossRefGoogle Scholar
  4. Danzon, P. M., & Epstein, A. (2008). Effects of regulation on drug launch and pricing in interdependent markets. NBER Working Paper 14041.Google Scholar
  5. DG Competition of the European Commission. (2009). Pharmaceutical sector inquiry final report.Google Scholar
  6. Donohue, J. M., Morden, N. E., Gellad, W. F., Bynum, J. P., Zhou, W., Hanlon, J. T., & Skinner, J. (2012). Sources of regional variation in Medicare Part D drug spending. New England Journal of Medicine, 366(6), 530–538.CrossRefGoogle Scholar
  7. Eurostat. (2017). Comparative price levels of consumer goods and services. Technical report. Eurostat.Google Scholar
  8. Goldberg, P., & Verboven, F. (2005). Market integration and convergence to the law of one price: Evidence from the European car market. Journal of International Economics, 65(1), 45–73.CrossRefGoogle Scholar
  9. Harhoff, D., Hoisl, K., Reichl, B., & van Pottelsberghe de la Potterie, B. (2009). Patent validation at the country level—the role of fees and translation costs. Research Policy, 38(9), 1423–1437.CrossRefGoogle Scholar
  10. Hemphill, S., & Sampat, B. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics, 31(2), 327–329.CrossRefGoogle Scholar
  11. Kyle, M. (2007). Pharmaceutical price controls and entry strategies. Review of Economics and Statistics, 89(1), 88–99.CrossRefGoogle Scholar
  12. Kyle, M. (2011). Strategic responses to parallel trade. B.E. Journal of Economic Analysis and Policy: Advances, 11(2), 1–34.CrossRefGoogle Scholar
  13. Kyle, M. (2016). Competition law, intellectual property, and the pharmaceutical sector. Antitrust Law Journal, 81(1), 1–45.Google Scholar
  14. Kyle, M. (2017). Economic analysis of supplementary protection certificates in Europe. Technical report. European Commission.Google Scholar
  15. Kyle, M., Allsbrook, J., & Schulman, K. (2008). Does reimportation reduce price differences for prescription drugs? Lessons from the European Union. Health Services Research, 43(4), 1308–1324.CrossRefGoogle Scholar
  16. Kyle, M., & McGahan, A. (2012). Investments in pharmaceuticals before and after TRIPS. Review of Economics and Statistics, 94(4), 1157–1172.CrossRefGoogle Scholar
  17. Maini, L., & Pammolli, F. (2017). Reference pricing as a deterrent to entry: Evidence from the European pharmaceutical market.Google Scholar
  18. Méjean, I., & Schwellnus, C. (2009). Price convergence in the European Union: Within firms or composition of firms? Journal of International Economics, 78(1), 1–10.CrossRefGoogle Scholar
  19. Ménière, Y., Maskus, K., Rudyk, I., Dechezleprêtre, A., Rujan, C., & Dussaux, D. (2017). Patents, trade and foreign direct investment in the European Union. Technical report. European Patent Office.Google Scholar
  20. OECD (2008). Pharmaceutical pricing policies in a global market.Google Scholar
  21. Reinhardt, U. E. (2001). Perspectives on the pharmaceutical industry. Health Affairs, 20(5), 136–149.CrossRefGoogle Scholar
  22. US Department of Health and Human Services. (2004). Variation in state Medicaid drug prices.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.MINES ParisTech (CERNA)PSL Research University and CEPRParisFrance

Personalised recommendations